ArticleCancer science2010

Adjuvant engineering for cancer immunotherapy: Development of a synthetic TLR2 ligand with increased cell adhesion.

Takashi Akazawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.